Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование тираголумаба в комбинации с атезолизумабом по сравнению с плацебо в комбинации с атезолизумабом у пациентов с ранее нелеченым местно-распространенным неоперабельным или метастатическим немелкоклеточным раком легкого, выбранным с помощью PD-L1 (SKYSCRAPER-01)

6 ноября 2026 г. обновлено: Hoffmann-La Roche

Фаза III, рандомизированное, двойное слепое, плацебо-контролируемое исследование тираголумаба, антитела против Tigit, в комбинации с атезолизумабом по сравнению с плацебо в комбинации с атезолизумабом у пациентов с ранее не леченными местнораспространенными нерезектабельными или метастатическими PD-L1-селектированными неоперабельными - Мелкоклеточный рак легкого

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

Обзор исследования

Тип исследования

Интервенционный

Регистрация (Действительный)

620

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • Queensland
      • Woolloongabba, Queensland, Австралия, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, Австралия, 3084
        • Austin Hospital Olivia Newton John Cancer Centre
      • Melbourne, Victoria, Австралия, 3000
        • Peter Maccallum Cancer Centre
      • Linz, Австрия, 4020
        • Ordensklinikum Linz Elisabethinen
      • Vienna, Австрия, 1140
        • Klinik Penzing
      • Vienna, Австрия, 1210
        • Krankenhaus Nord - Klinik Floridsdorf
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Бразилия, 98700-000
        • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    • São Paulo
      • Barretos, São Paulo, Бразилия, 14784-400
        • Hospital de Cancer de Barretos
      • Budapest, Венгрия, 1121
        • Orszagos Koranyi TBC es Pulmonologiai Intezet
      • Mátraháza, Венгрия, 3233
        • Matrai Gyogyintezet
      • Szolnok, Венгрия, 5004
        • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
      • Frankfurt, Германия, 60488
        • Krankenhaus Nordwest
      • Großhansdorf, Германия, 22927
        • LungenClinic Großhansdorf GmbH
      • Halle, Германия, 06120
        • Krankenhaus Martha-Maria Halle-Doelau gGmbH
      • Immenhausen, Германия, 34376
        • Fachklinik für Lungenerkrankungen
      • Löwenstein, Германия, 74245
        • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
      • Münster, Германия, 48153
        • Gemeinschaftspraxis für Hämatologie und Onkologie
      • Stuttgart, Германия, 70376
        • Klinik Schillerhöhe
      • Athens, Греция, 185 47
        • Metropolitan Hospital
      • Athens, Греция, 104 31
        • Sotiria Hospital
      • Larissa, Греция, 411 10
        • University Hospital of Larissa
      • Thessaloniki, Греция, 570 01
        • Diavalkaniko Hospital
      • Madrid, Испания, 28041
        • Hospital 12 de Octubre
      • Madrid, Испания, 28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Madrid, Испания, 41013
        • Hospital Universitario Virgen del Rocío
      • Málaga, Испания, 29010
        • Hospital Regional Universitario de Malaga
      • Zaragoza, Испания, 50009
        • Hosp Clinico Univ Lozano Blesa
    • Barcelona
      • Badalona, Barcelona, Испания, 08916
        • Hospital Universitario Germans Trias i Pujol
    • Campania
      • Naples, Campania, Италия, 80131
        • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    • Lazio
      • Rome, Lazio, Италия, 00151
        • Azienda Ospedaliera San Camillo Forlanini
      • Rome, Lazio, Италия, 00168
        • Policlinico Universitario "Agostino Gemelli"
    • Lombardy
      • Milan, Lombardy, Италия, 20141
        • Irccs Istituto Europeo di Oncologia (IEO)
      • Monza, Lombardy, Италия, 20900
        • Asst Di Monza
      • Rozzano, Lombardy, Италия, 20089
        • Istituto Clinico Humanitas
    • Piedmont
      • Orbassano, Piedmont, Италия, 10043
        • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    • Umbria
      • Perugia, Umbria, Италия, 06156
        • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    • Veneto
      • Padova, Veneto, Италия, 35128
        • IOV - Istituto Oncologico Veneto - IRCCS
      • Beijing, Китай, 100142
        • Beijing Cancer Hospital
      • Changchun, Китай, 130021
        • The First Hospital of Jilin University
      • Chengdu, Китай, 610041
        • West China Hospital, Sichuan University
      • Chongqing, Китай, 400030
        • Chongqing Cancer Hospital
      • Fuzhou, Китай, 350014
        • Fujian Cancer Hospital
      • Haikou, Китай, 570311
        • Hainan General Hospital
      • Hangzhou, Китай, 310016
        • Sir Run Run Shaw Hospital Zhejiang University
      • Harbin, Китай, 150081
        • Harbin Medical University Cancer Hospital
      • Jinan, Китай, 250013
        • Jinan Central Hospital
      • Meizhou, Китай, 514031
        • Meizhou People's Hospital
      • Nanchang, Китай, 330200
        • The 1st Affiliated Hospital of Nanchang Unversity
      • Nantong, Китай, 226361
        • Nantong Tumor Hospital
      • Shanghai, Китай, 200433
        • Shanghai Pulmonary Hospital
      • Shanghai, Китай, 200032
        • Zhongshan Hospital Fudan University
      • Shanghai, Китай, 200120
        • Fudan University Shanghai Cancer Center
      • Wuhan, Китай, 430022
        • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
      • Xi'an, Китай, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Zhejiang, Китай, 310022
        • Zhejiang Cancer Hospital
    • Mexico CITY (federal District)
      • México, Mexico CITY (federal District), Мексика, 06100
        • Cryptex Investigacion Clinica SA de CV
    • Nuevo León
      • Monterrey, Nuevo León, Мексика, 64710
        • AVIX Investigación Clínica S.C
    • Querétaro
      • Querétaro City, Querétaro, Мексика, 76000
        • Cuidados oncologicos
      • 's-Hertogenbosch, Нидерланды, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Ede, Нидерланды, 6716 RP
        • Ziekenhuis Gelderse Vallei
      • Leeuwarden, Нидерланды, 8934 AD
        • Frisius MC Leeuwarden
      • The Hague, Нидерланды, 2545 AA
        • Hagaziekenhuis, locatie Leyweg
      • Arequipa, Перу, 5154
        • Instituto Regional de Enfermedades Neoplásicas del Sur
      • Lima, Перу, 15038
        • Instituto Nacional de Enfermedades Neoplasicas
      • Lima, Перу, Lima 41
        • Clinica Internacional, Sede San Borja
      • San Isidro, Перу, Lima 27
        • Clinica Ricardo Palma
      • Gda?sk, Польша, 80-214
        • Uniwersyteckie Centrum Kliniczne
      • Olsztyn, Польша, 10-357
        • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
      • Poznan, Польша, 60-569
        • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
    • Moscow Oblast
      • Moscow, Moscow Oblast, Россия, 143422
        • MEDSI Clinical Hospital on Pyatnitsky Highway
      • Moscow, Moscow Oblast, Россия, 105229
        • Main Military Clinical Hospital named after N.N. Burdenko
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Россия, 194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg, Sankt-Peterburg, Россия, 189646
        • Institute of Oncology
      • Saint Petersburg, Sankt-Peterburg, Россия, 197089
        • St. Petersburg Med Univ
      • Saint Petersburg, Sankt-Peterburg, Россия, 197758
        • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
      • Belgrade, Сербия, 11000
        • Clinical Center of Serbia
      • Belgrade, Сербия, 11080
        • University Hospital Medical Center Bezanijska kosa
    • Colorado
      • Denver, Colorado, Соединенные Штаты, 80220
        • Rocky Mountain Cancer Center - Denver
    • Connecticut
      • New Haven, Connecticut, Соединенные Штаты, 06520
        • Yale Cancer Center
    • Florida
      • St. Petersburg, Florida, Соединенные Штаты, 33705
        • SCRI Florida Cancer Specialists North
      • Tallahassee, Florida, Соединенные Штаты, 32308
        • SCRI Florida Cancer Specialists PAN
    • Minnesota
      • Saint Paul, Minnesota, Соединенные Штаты, 55102
        • US oncology research at Minnesota Oncology
    • Tennessee
      • Nashville, Tennessee, Соединенные Штаты, 37203
        • SCRI Oncology Partners
    • Virginia
      • Fairfax, Virginia, Соединенные Штаты, 22031
        • Virginia Cancer Specialists (Fairfax) - USOR
      • Salem, Virginia, Соединенные Штаты, 24153
        • Onc & Hem Assoc SW Virginia
      • Bangkok, Таиланд, 10330
        • Chulalongkorn Hospital
      • Bangkok, Таиланд, 10400
        • Ramathibodi Hospital
      • Bangkok, Таиланд, 10700
        • Faculty of Med. Siriraj Hosp.
      • Songkhla, Таиланд, 90110
        • Songklanagarind Hospital
      • Guishan Dist., Тайвань, 33305
        • Chang Gung Memorial Hospital - Linkou Branch
      • Kaohsiung City, Тайвань, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City, Тайвань, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Тайвань, 23561
        • Taipei Medical University ?Shuang Ho Hospital
      • Taichung, Тайвань, 407
        • Taichung Veterans General Hospital
      • Tainan, Тайвань, 704
        • National Cheng Kung Uni Hospital
      • Taipei, Тайвань, 112
        • Taipei Veterans General Hospital
      • Zhongzheng Dist., Тайвань, 10048
        • National Taiwan University Hospital
      • Adana, Турция (Туркие), 01120
        • Adana Baskent University Hospital
      • Ankara, Турция (Туркие), 06100
        • Hacettepe University Medical Faculty
      • Istanbul, Турция (Туркие), 34098
        • Istanbul University Cerrahpasa Faculty of Medicine
      • Izmir, Турция (Туркие), 35110
        • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
      • Kadiköy, Турция (Туркие), 34722
        • Goztepe Prof.Dr. Suleyman Yalcin City Hospital
      • Malatya, Турция (Туркие), 44280
        • Inonu University Medical Faculty of Medicine
      • Kryvyi Rih, Украина, 50048
        • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
      • Uzhhorod, Украина, 88000
        • Uzhgorod Nat. University Central Municip Hosp
      • Bern, Швейцария, 3010
        • Inselspital Bern
      • Lausanne, Швейцария, 1011
        • CHUV
      • Sankt Gallen, Швейцария, 9000
        • HOCH Health Ostschweiz, Kantonsspital St. Gallen
      • Cheongju-si, Южная Корея, 28644
        • Chungbuk National University Hospital
      • Gyeonggi-do, Южная Корея, 13620
        • Seoul National University Bundang Hospital
      • Gyeonggi-do, Южная Корея, 16499
        • Ajou University Medical Center
      • Incheon, Южная Корея, 21565
        • Gachon University Gil Medical Center
      • Jeollanam-do, Южная Корея, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, Южная Корея, 03080
        • Seoul National University Hospital
      • Seoul, Южная Корея, 05505
        • Asan Medical Center
      • Seoul, Южная Корея, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Южная Корея, 08308
        • Korea University Guro Hospital
      • Seoul, Южная Корея, 6351
        • Samsung Medical Center
      • Seoul, Южная Корея, 03181
        • Kangbuk Samsung Medical Center
      • Suwon, Южная Корея, 442-723
        • St. Vincent's Hospital
      • Aichi, Япония, 464-8681
        • Aichi Cancer Center
      • Chiba, Япония, 277-8577
        • National Cancer Center Hospital East
      • Fukuoka, Япония, 812-8582
        • Kyushu University Hospital
      • Miyagi, Япония, 980-0873
        • Sendai Kousei Hospital
      • Niigata, Япония, 951-8566
        • Niigata Cancer Center Hospital
      • Osaka, Япония, 589-8511
        • Kindai University Hospital
      • Osaka, Япония, 541-8567
        • Osaka International Cancer Institute
      • Saitama, Япония, 362-0806
        • Saitama Cancer Center
      • Sakaishi, Япония, 591-8555
        • NHO Kinki-Chuo Chest Medical Center
      • Shizuoka, Япония, 411-8777
        • Shizuoka Cancer Center
      • Tokyo, Япония, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Япония, 135-8550
        • The Cancer Institute Hospital of JFCR

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Тройной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Tiragolumab + Atezolizumab

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Другие имена:
  • Тецентрик

Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Другие имена:
  • MTIG7192A
Плацебо Компаратор: Placebo + Atezolizumab

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Другие имена:
  • Тецентрик

Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
Временное ограничение: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
Временное ограничение: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
Временное ограничение: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
Временное ограничение: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
Временное ограничение: Up to 65.1 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 65.1 months
China Cohort: Number of Participants With AEs
Временное ограничение: Up to 49.3 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
Временное ограничение: Up to 65.1 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
Временное ограничение: Up to 49.3 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 49.3 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
Временное ограничение: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
Временное ограничение: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: OS in the SAS
Временное ограничение: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the SAS
Временное ограничение: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
Временное ограничение: Up to approximately 54.6 months

Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to approximately 54.6 months
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
Временное ограничение: Up to 49.3 months

Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to 49.3 months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Временное ограничение: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Временное ограничение: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Временное ограничение: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Временное ограничение: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Временное ограничение: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Временное ограничение: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
Временное ограничение: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
Временное ограничение: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
Временное ограничение: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
Временное ограничение: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
Временное ограничение: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
Временное ограничение: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Временное ограничение: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Временное ограничение: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Временное ограничение: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Временное ограничение: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Временное ограничение: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Временное ограничение: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Временное ограничение: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Tiragolumab
Временное ограничение: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months
Global Cohort: Number of Participants With ADAs to Atezolizumab
Временное ограничение: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Atezolizumab
Временное ограничение: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Директор по исследованиям: Clinical Trial, Hoffmann-La Roche

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

4 марта 2020 г.

Первичное завершение (Действительный)

30 декабря 2025 г.

Завершение исследования (Действительный)

30 декабря 2025 г.

Даты регистрации исследования

Первый отправленный

2 марта 2020 г.

Впервые представлено, что соответствует критериям контроля качества

2 марта 2020 г.

Первый опубликованный (Действительный)

4 марта 2020 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

9 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

6 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться